Sources and Therapeutic Strategies of Mesenchymal Stem Cells in Regenerative Medicine

Kamal, Mohamed M.; Kassem, Dina H.; Haider, Khawaja Husnain

doi:10.1007/978-981-16-6016-0_2-1

Cited by 34 publications

(4 citation statements)

References 179 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, using iPSCs (considered surrogate ESCs) has tumorigenic potential due to genomic instability induced during reprogramming[ 37 ]. MSCs from amongst the adult tissue-derived stem cells have gained considerable attention in nerve regeneration studies in experimental animal models with their self-renewal, robust nature, excellent cell biology, and multipotentiality[ 38 ]. Table 1 summarizes the data published by various recently published experimental animal studies using MSCs.…”

Section: Mscs and Pni Repairmentioning

confidence: 99%

Mesenchymal stem cells’ “garbage bags” at work: Treating radial nerve injury with mesenchymal stem cell-derived exosomes

Mushtaq,

Zineldeen,

Mateen

et al. 2024

World J Stem Cells

Self Cite

View full text Add to dashboard Cite

Unlike central nervous system injuries, peripheral nerve injuries (PNIs) are often characterized by more or less successful axonal regeneration. However, structural and functional recovery is a senile process involving multifaceted cellular and molecular processes. The contemporary treatment options are limited, with surgical intervention as the gold-standard method; however, each treatment option has its associated limitations, especially when the injury is severe with a large gap. Recent advancements in cell-based therapy and cell-free therapy approaches using stem cell-derived soluble and insoluble components of the cell secretome are fast-emerging therapeutic approaches to treating acute and chronic PNI. The recent pilot study is a leap forward in the field, which is expected to pave the way for more enormous, systematic, and well-designed clinical trials to assess the therapeutic efficacy of mesenchymal stem cell-derived exosomes as a bio-drug either alone or as part of a combinatorial approach, in an attempt synergize the best of novel treatment approaches to address the complexity of the neural repair and regeneration.

show abstract

Section: Mscs and Pni Repairmentioning

confidence: 99%

Mesenchymal stem cells’ “garbage bags” at work: Treating radial nerve injury with mesenchymal stem cell-derived exosomes

Mushtaq,

Zineldeen,

Mateen

et al. 2024

World J Stem Cells

Self Cite

View full text Add to dashboard Cite

show abstract

“…Mesodermal in origin, MSCs can be obtained from diverse tissue sources [ 7 ]. They are easy to isolate and propagate in vitro and exhibit superior cell biology, with minimal immunogenicity and excellent immunomodulatory properties [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Dose-response relationship of MSCs as living Bio-drugs in HFrEF patients: a systematic review and meta-analysis of RCTs

Ahmed,

Zain Al-Abeden,

Al Abdin

et al. 2024

Stem Cell Res Ther

View full text Add to dashboard Cite

Background Mesenchymal stem cells (MSCs) have emerged as living biodrugs for myocardial repair and regeneration. Recent randomized controlled trials (RCTs) have reported that MSC-based therapy is safe and effective in heart failure patients; however, its dose-response relationship has yet to be established. We aimed to determine the optimal MSC dose for treating HF patients with reduced ejection fraction (EF) (HFrEF). Methods The preferred reporting items for systematic reviews and meta-analyses (PRISMA) and Cochrane Handbook guidelines were followed. Four databases and registries, i.e., PubMed, EBSCO, clinicaltrials.gov, ICTRP, and other websites, were searched for RCTs. Eleven RCTs with 1098 participants (treatment group, n = 606; control group, n = 492) were selected based on our inclusion/exclusion criteria. Two independent assessors extracted the data and performed quality assessments. The data from all eligible studies were plotted for death, major adverse cardiac events (MACE), left ventricular ejection fraction (LVEF), left ventricular end-systolic volume (LVESV), and 6-minute walk distance (6-MWD) as safety, efficacy, and performance parameters. For dose-escalation assessment, studies were categorized as low-dose (< 100 million cells) or high-dose (≥ 100 million cells). Results MSC-based treatment is safe across low and high doses, with nonsignificant effects. However, low-dose treatment had a more significant protective effect than high-dose treatment. Subgroup analysis revealed the superiority of low-dose treatment in improving LVEF by 3.01% (95% CI; 0.65–5.38%) compared with high-dose treatment (-0.48%; 95% CI; -2.14-1.18). MSC treatment significantly improved the 6-MWD by 26.74 m (95% CI; 3.74–49.74 m) in the low-dose treatment group and by 36.73 m (95% CI; 6.74–66.72 m) in the high-dose treatment group. The exclusion of studies using ADRCs resulted in better safety and a significant improvement in LVEF from low- and high-dose MSC treatment. Conclusion Low-dose MSC treatment was safe and superior to high-dose treatment in restoring efficacy and functional outcomes in heart failure patients, and further analysis in a larger patient group is warranted.

show abstract

“…17,18 Thus, aluminum-induced AD model can be used for investigating the pathogenesis and novel therapeutics for AD. 18,19 Recently, mesenchymal stem cells (MSCs) transplantation has emerged as an efficient therapeutic strategy for various diseases, [20][21][22] including neurodegenerative disorders. 11,23,24 Among the various types of stem cells, adipose tissue-derived MSCs (Ad-MSCs) specifically provide several advantages compared to other types of stem cells.…”

Section: Introductionmentioning

confidence: 99%

“…A growing body of evidence has shown that Ad‐MSCs exhibit potential beneficial impact in the rescue of AD, particularly through reducing the size of Aβ plaques and mitigation of cognitive decline 36 . In fact, Ad‐MSCs have been reported to mediate their actions through various mechanisms, including their immunomodulatory abilities, tissue regenerative capacity, and most importantly via the secretion of various cytokines, growth factors, and extracellular vesicles which employ various bioactive mediators, immunomodulatory, and anti‐inflammatory molecules 22,37–40 . Yet, further research is warranted to fully elucidate the molecular factors that mediate their various therapeutic beneficial effects in the context of different diseases.…”

Section: Introductionmentioning

confidence: 99%

Adipose tissue‐derived mesenchymal stem cells ameliorate cognitive impairment in Alzheimer's disease rat model: Emerging role of SIRT1

et al. 2023

View full text Add to dashboard Cite

Alzheimer's disease (AD) is a complex form of neurodegenerative dementia. Growing body of evidence supports the cardinal role of sirtuin1 (SIRT1) in neurodegeneration and AD development. Recently, adipose tissue‐derived mesenchymal stem cells (Ad‐MSCs) have made their mark for a wide array of regenerative medicine applications, including neurodegenerative disorders. Therefore, the present study aimed to investigate the therapeutic potential of Ad‐MSCs in AD rat model, and to explore the possible implication of SIRT1. Ad‐MSCs were isolated from rat epididymal fat pads and properly characterized. Aluminum chloride was used to induce AD in rats, and afterward, a group of AD‐induced rats received a single dose of Ad‐MSCs (2 × 106 cell, I.V per rat). One month after Ad‐MSCs transplantation, behavioral tests were done, brain tissues were collected, then histopathological and biochemical assessments were performed. Amyloid beta and SIRT1 levels were determined by enzyme‐linked immunosorbent assay. Whereas expression levels of neprilysin, BCL2 associated X protein, B‐cell lymphoma‐2, interleukin‐1β, interleukin‐6, and nerve growth factor in hippocampus and frontal cortex brain tissues were assessed using reverse transcriptase quantitative polymerase chain reaction. Our data demonstrated that transplantation of Ad‐MSCs alleviated cognitive impairment in AD rats. Additionally, they exhibited anti‐amyloidogenic, antiapoptotic, anti‐inflammatory, as well as neurogenic effects. Furthermore, Ad‐MSCs were found to possibly mediate their therapeutic effects, at least partially, via modulating both central and systemic SIRT1 levels. Hence, the current study portrays Ad‐MSCs as an effective therapeutic approach for AD management and opens the door for future investigations to further elucidate the role of SIRT1 and its interrelated molecular mediators in AD.

show abstract

Sources and Therapeutic Strategies of Mesenchymal Stem Cells in Regenerative Medicine

Cited by 34 publications

References 179 publications

Mesenchymal stem cells’ “garbage bags” at work: Treating radial nerve injury with mesenchymal stem cell-derived exosomes

Mesenchymal stem cells’ “garbage bags” at work: Treating radial nerve injury with mesenchymal stem cell-derived exosomes

Dose-response relationship of MSCs as living Bio-drugs in HFrEF patients: a systematic review and meta-analysis of RCTs

Adipose tissue‐derived mesenchymal stem cells ameliorate cognitive impairment in Alzheimer's disease rat model: Emerging role of SIRT1

Contact Info

Product

Resources

About